Attacking Tumors at the Source

Our technology provides a new opportunity to “drug the undruggable”. We target specific protein-protein interactions, which when disrupted can lead to a “pro-cell death” fate or modulated immune response in targeted cells.

View Our Platform

Enabling Treatments Aimed at Dysregulated PPIs

Our lead candidate, ST101, is a cell-penetrating peptide antagonist of C/EBPβ designed to target various solid tumors (including breast cancer, melanoma, prostate cancer, GBM, lung cancer, and AML) and hematologic malignancies.

In July 2020, we initiated the first clinical trial for ST101, which has also been granted Orphan Drug Designation for the treatment of glioma and AML by the U.S. FDA.

More About ST101

Latest News

Sapience Therapeutics Awarded SBIR Grant from National Cancer Institute (NCI) of the National Institutes of Health (NIH) for ST316, its β-catenin antagonist peptide (BCAP) Program

Sapience Therapeutics Announces Oral Presentation on ST101 at the AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics 2021

Sapience Therapeutics Announces Poster Presentation on ST101 at the European Society for Medical Oncology (ESMO) Congress 2021

Sapience Therapeutics Commences Dosing in Final Dose-Escalation Cohort of Ongoing Phase 1-2 Study of ST101

Sapience Therapeutics to Participate at SVB Leerink Biopharma Private Company Connect

Sapience Therapeutics to Present at BIO Digital 2021

Sapience Therapeutics Enters Into Collaboration with National Cancer Institute (NCI) to Study ST101 Response in Specialized Tumor Models

Sapience Therapeutics Awarded SBIR Phase I Grant from National Institute of Allergy and Infectious Diseases

Sapience Therapeutics Announces Multiple Posters, Including Late-Breaker, at the American Association for Cancer Research (AACR) Annual Meeting 2021

Email Alerts

Stay informed and receive company updates straight to your inbox.

Sign up today